Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF.

Tumor necrosis factor (TNF) has marked effects on permeability and procoagulant activity on tumor-associated neovasculature when used in isolation perfusion, the latter effect primarily mediated via induction of cell surface expression of tissue factor (TF) on endothelial tissue. However, the cellular events that result in rapid alterations in endothelial cell (EC) permeability after intravascular TNF administration in isolation perfusion are not well characterized. We demonstrate that short exposure intervals to TNF induces TF expression on ECs but has no effect on permeability as assessed by flux of Evans blue-bound albumin across confluent EC monolayers using a 2-compartment model under basal culture conditions. However, a rapid and significant increase in EC permeability occurred with TNF in the presence of factor VIII-deficient plasma. Permeability was induced only with luminal versus abluminal TNF exposure and was blocked by antithrombin III, TF pathway inhibitor, or anti-TF antibody cotreatment. These data indicate that EC surface expression of TF and extrinsic clotting factors are critical in augmenting capillary leak following intravascular TNF administration. Alterations in permeability were associated with intercellular gap formation at sites of down-regulation of vascular endothelial (VE)-cadherin expression, the primary endothelial intercellular adhesion molecule, and intracellular contraction and alignment of F-actin cytoskeletal elements. Rapid induction of TF by TNF may be the primary EC response that results in alterations in permeability and procoagulant activity observed following intravascular TNF administration in isolation perfusion.

[1]  M. Gnant,et al.  Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. , 2000, Cytokine.

[2]  P. Schlag,et al.  Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. , 1997, Seminars in oncology.

[3]  H. Gerlach,et al.  Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas , 1988, The Journal of experimental medicine.

[4]  T S Edgington,et al.  Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Inbar,et al.  High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation , 1997, Cancer.

[6]  P. Carmeliet Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[7]  D. Fraker,et al.  Isolated limb perfusion for malignant melanoma. , 1996, Seminars in surgical oncology.

[8]  H. Gerlach,et al.  Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins , 1989, The Journal of experimental medicine.

[9]  J. Kirkwood,et al.  Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. , 1995, The cancer journal from Scientific American.

[10]  H. Alexander,et al.  Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  W. Kisiel,et al.  Mechanism of the Tumor Necrosis Factor α-mediated Induction of Endothelial Tissue Factor (*) , 1995, The Journal of Biological Chemistry.

[12]  H. Gerlach,et al.  Enhanced responsiveness of endothelium in the growing/motile state to tumor necrosis factor/cachectin [published erratum appears in J Exp Med 1989 Nov 1;170(5):1793] , 1989, The Journal of experimental medicine.

[13]  G. Bieler,et al.  Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.

[14]  A. Eggermont,et al.  Isolated limb perfusion in primary and recurrent melanoma: indications and results. , 1998, Seminars in surgical oncology.

[15]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[16]  T Vernet,et al.  Alteration of Endothelial Cell Monolayer Integrity Triggers Resynthesis of Vascular Endothelium Cadherin* , 1998, The Journal of Biological Chemistry.

[17]  A. Eggermont,et al.  Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) , 1994 .

[18]  S. Libutti,et al.  In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). , 1999, Cancer research.

[19]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[20]  D. Fraker,et al.  Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Fallon,et al.  Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[22]  S. Sleijfer,et al.  Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments. , 1997, Journal of immunotherapy.

[23]  V. Devita,et al.  Biologic Therapy of Cancer , 1992 .

[24]  B. Feig Isolated limb perfusion for extremity sarcoma , 2000, Current oncology reports.

[25]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Luther,et al.  Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. , 1994, The Journal of clinical investigation.

[27]  D. Fraker,et al.  Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Chioléro,et al.  Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. , 1995, Chest.

[29]  P. Neumann,et al.  Protein kinase C-α mediates endothelial barrier dysfunction induced by TNF-α , 2000 .

[30]  P. Flemming,et al.  First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. , 1998, Surgery.

[31]  Donald W. Miller,et al.  Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure. , 1999, Life sciences.

[32]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.